Prospective cohort study demonstrates safe delabeling of sulfa allergies in immunocompromised hosts, implying improved antibiotic utilization.
In this prospective cohort study, trimethoprim-sulfamethoxazole direct oral challenge (DOC) for hospitalized adults reporting a low-risk sulfa antibiotic allergy was safe with 75/76 (99%) inpatients delabeled. Within 90-days of DOC, immunocompromised patients were more likely to receive trimethoprim-sulfamethoxazole, compared with non-immunocompromised patients (adjusted OR 5.6 95% CI 1.3, 23.0).
No takes yet. Share an insight, caveat, or question.
Mitri et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: